Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645404 | 0.94 | TGFBR1 (0.64) | TGFBR1TGFB1 | |
| SCHEMBL22186847 | 0.89 | TGFBR1 (0.60) | TGFBR1TGFB1 | |
| SCHEMBL17645445 | 0.88 | TGFBR1 (0.53) | TGFBR1TGFB1 | |
| SCHEMBL24263214 | 0.85 | TGFBR1 (0.52) | TGFBR1TGFB1 | |
| SCHEMBL17645399 | 0.85 | TGFBR1 (0.52) | TGFBR1TGFB1 | |
| SCHEMBL28397649 | 0.85 | TGFBR1 (0.54) | TGFBR1TGFB1 | |
| SCHEMBL28401970 | 0.85 | TGFBR1 (0.50) | TGFBR1TGFB1 | |
| SCHEMBL22186882 | 0.84 | TGFBR1 (0.51) | TGFBR1TGFB1 | |
| SCHEMBL30619329 | 0.84 | TGFBR1 (0.60) | TGFBR1TGFB1 | |
| SCHEMBL28888969 | 0.84 | TGFBR1 (0.57) | TGFBR1TGFB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204377-B1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3204377-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | Eli Lilly and Company (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | TGFBR1 1/4885TGFB1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.